💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Spring Bank's HBV candidate SB 9200 shows favorable safety profile in mid-stage study

Published 05/23/2017, 04:37 PM
© Reuters.  Spring Bank's HBV candidate SB 9200 shows favorable safety profile in mid-stage study
FSTX
-
  • Top-line results from a Phase 2a clinical trial, ACHIEVE, assessing Spring Bank Pharmaceuticals' (NASDAQ:SBPH) SB 9200 for the treatment of chronic hepatitis B virus (HBV) infection showed an encouraging safety profile.
  • There were no serious adverse events observed during the 12-week study. Treatment-emergent adverse events were mild to moderate, with no interferon-like side effects. There were no Grade 3 (serious) laboratory abnormalities, but ALT flares (rapid increases in the liver enzyme) were observed in three patients, but only one was receiving SB 9200. This instance was categorized as a beneficial immune flare because it was associated with a significant reduction in HBV DNA.
  • Detailed results will be submitted for presentation at a future medical conference.
  • Management will host a conference call tomorrow morning at 8:00 am ET to discuss the data.
  • Now read: Syndax Pharmaceuticals (SNDX) Presents At UBS Global Healthcare Conference 2017 - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.